SYNLAB International GmbH
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
SYNLAB International GmbH - overview
Established
1998
Location
Munich, -, Germany
Primary Industry
Healthcare
About
Based in Munich, Germany, and established in 1998, SYNLAB International GmbH aka SYNLAB Group, fka Synlab Holding operates as a provider of medical diagnostics and testing services. In October 2015, Cinven merged Labco S. A. with Synlab Holding GmbH and created the brand, SYNLAB, and in April 2021, the company started trading on the regulated market of the Frankfurt Stock Exchange under the ticker symbol SYAB.
As of March 2022, SYNLAB Group is being led by its CEO, Mathieu Floreani. In September 2023, Cinven agreed to acquire a 57. 2% majority stake in the company. SYNLAB Group offers a wide range of medical diagnostics and testing services including routine and speciality checkups (clinical biological testing), histological and cytological sample collection and testing (anatomical pathology testing), as well as diagnostic imaging such as nuclear imaging.
The company operates B2B (Business-to-Business) channel where the services are offered to patients through third parties including hospitals, clinics, practising doctors, and other companies, as well as D2C (Direct-to-Customer) channel, where patients are offered services directly through the company’s centres. Additionally, the firm provides veterinary diagnostics services in selected countries and furthermore offers training programmes, and seminars through SYNLAB Academy. As of March 2022, SYNLAB Group has over 500 laboratories and more than 1,800 blood sample collection centres and offers nearly 5,000 routine and speciality testing services for its clients across 36 countries worldwide. The company generated a revenue of EUR 3.
76 billion and EUR 2. 62 billion in the financial year 2021 and 2020 respectively.
Current Investors
Cinven
Primary Industry
Healthcare
Sub Industries
Education/Training, Diagnostic, Medical & Imaging Laboratories
Website
www.synlab.com
Verticals
HealthTech
Company Stage
Mature
Total Amount Raised
Subscriber access only
SYNLAB International GmbH - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Add-on, Corporate Carve Out, Trade Sale | Completed | SYNLAB Romania | - | ||||||||
| Add-on, Corporate Carve Out, Trade Sale | Completed | Synlab Macedonia | - | ||||||||
| Add-on, Corporate Carve Out, Trade Sale | Completed | SYNLAB Slovenia | - | ||||||||
| Add-on, Corporate Carve Out, Trade Sale | Completed | SYNLAB Cyprus | - | ||||||||
| Add-on, Corporate Carve Out, Trade Sale | Completed | SYNLAB Türkiye | - |
Displaying 1 - 5 of 23
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.